Search
for
Sort by
Research 241–270 of 584
- Alopecia Universalis and Chronic Graft-vs-Host Disease Treated With Ruxolitinib
- Ruxolitinib reverses alopecia areata via a triple mechanism: JAK-STAT inhibition, localized oxidative stress attenuation and selective apoptosis modulation
- Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with <i>AIRE</i> gene mutation (autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy, APECED syndrome) treated with ruxolitinib
- A Successful Treatment of Alopecia Universalis with Ruxolitinib
- A Single Subcutaneous Dose of BMD-1141 Stimulates Hair Regrowth Comparable to Daily, High-Dose Ruxolitinib in a Mouse Model of Alopecia Areata.
- BH02 Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with the <i>AIRE</i> gene mutation treated with ruxolitinib
- ISID1108 - Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata.
- 1108 Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata
- Topical Ruxolitinib for the Treatment of Alopecia Universalis
- Topical Ruxolitinib for Folliculitis Decalvans
- Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
- The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1
- Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
- Resident Memory T Cells in Autoimmune Skin Diseases
- Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study
- Emerging treatments in alopecia
- STAT5 Activation in the Dermal Papilla Is Important for Hair Follicle Growth Phase Induction
- A novel therapeutic paradigm for patients with extensive alopecia areata
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?
- Alopecia Areata: An Update on Treatment Options for Children
- The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells
- Alopecia areata – Current understanding and management
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature
- Janus Kinase Inhibitors against Other Biological Treatments in Alopecia Areata
- [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
- 691 Topical curcumin promotes induction of the murine hair cycle